Format
Sort by
Items per page

Send to

Choose Destination

Best matches for huntington-study-group:

Search results

Items: 1 to 20 of 117

1.

High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease.

Ciarochi JA, Liu J, Calhoun V, Johnson H, Misiura M, Bockholt HJ, Espinoza FA, Caprihan A, Plis S, Turner JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Brain Sci. 2018 Jun 22;8(7). pii: E116. doi: 10.3390/brainsci8070116.

2.

Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease.

Liu J, Ciarochi J, Calhoun VD, Paulsen JS, Bockholt HJ, Johnson HJ, Long JD, Lin D, Espinoza FA, Misiura MB, Caprihan A, Turner JA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Front Neurol. 2018 Mar 29;9:190. doi: 10.3389/fneur.2018.00190. eCollection 2018.

3.

Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.

Tanner C, Marder K, Eberly S, Biglan K, Oakes D, Shoulson I; Huntington Study Group Prospective Huntington At-Risk Observational Study Investigators.

Mov Disord. 2018 Mar;33(3):472-478. doi: 10.1002/mds.27239. Epub 2018 Jan 3.

PMID:
29297592
4.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

PMID:
29142089
6.

The CREST-E study of creatine for Huntington disease: A randomized controlled trial.

Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD; Huntington Study Group CREST-E Investigators and Coordinators.

Neurology. 2017 Aug 8;89(6):594-601. doi: 10.1212/WNL.0000000000004209. Epub 2017 Jul 12.

7.

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.

Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators.

JAMA Neurol. 2017 Aug 1;74(8):977-982. doi: 10.1001/jamaneurol.2017.1352.

8.

Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.

Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Hum Brain Mapp. 2017 Oct;38(10):5035-5050. doi: 10.1002/hbm.23713. Epub 2017 Jun 28.

PMID:
28657159
9.

Dynamic Prediction of Motor Diagnosis in Huntington's Disease Using a Joint Modeling Approach.

Li K, Furr-Stimming E, Paulsen JS, Luo S; PREDICT-HD Investigators of the Huntington Study Group.

J Huntingtons Dis. 2017;6(2):127-137. doi: 10.3233/JHD-170236.

10.

Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study.

Westervelt HJ, Bernier RA, Faust M, Gover M, Bockholt HJ, Zschiegner R, Long JD, Paulsen JS; PREDICT-HD Investigators; Coordinators of the Huntington Study Group.

Int J Methods Psychiatr Res. 2017 Sep;26(3). doi: 10.1002/mpr.1534. Epub 2017 Feb 17.

PMID:
28211597
11.

Abstracts from HSG 2016: Discovering Our Future, the 23rd Annual Meeting of the Huntington Study Group (HSG).

[No authors listed]

Neurotherapeutics. 2017 Jan;14(1):227-251. doi: 10.1007/s13311-016-0482-y. No abstract available.

12.

Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD.

Downing NR, Lourens S, De Soriano I, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Huntingtons Dis. 2016 Dec 15;5(4):357-368.

PMID:
27983559
13.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

14.

Identification of extreme motor phenotypes in Huntington's disease.

Braisch U, Hay B, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M; REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):283-294. doi: 10.1002/ajmg.b.32514. Epub 2016 Nov 21.

PMID:
27868347
15.

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Quaid KA, Eberly SW, Kayson-Rubin E, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators and Coordinators.

Clin Genet. 2017 Jun;91(6):824-831. doi: 10.1111/cge.12893. Epub 2016 Nov 24.

16.

Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome.

Ciarochi JA, Calhoun VD, Lourens S, Long JD, Johnson HJ, Bockholt HJ, Liu J, Plis SM, Paulsen JS, Turner JA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Front Neurol. 2016 Sep 21;7:147. eCollection 2016.

17.

Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease.

Salem L, Saleh N, Désaméricq G, Youssov K, Dolbeau G, Cleret L, Bourhis ML, Azulay JP, Krystkowiak P, Verny C, Morin F, Moutereau S; French Huntington Study Group, Bachoud-Lévi AC, Maison P.

PLoS One. 2016 Sep 14;11(9):e0162890. doi: 10.1371/journal.pone.0162890. eCollection 2016.

18.

Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.

Harrington DL, Long JD, Durgerian S, Mourany L, Koenig K, Bonner-Jackson A, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group, Rao SM.

Mov Disord. 2016 Nov;31(11):1664-1675. doi: 10.1002/mds.26803. Epub 2016 Sep 13.

19.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

20.

Linking white matter and deep gray matter alterations in premanifest Huntington disease.

Faria AV, Ratnanather JT, Tward DJ, Lee DS, van den Noort F, Wu D, Brown T, Johnson H, Paulsen JS, Ross CA, Younes L, Miller MI; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Neuroimage Clin. 2016 Feb 26;11:450-60. doi: 10.1016/j.nicl.2016.02.014. eCollection 2016.

Supplemental Content

Loading ...
Support Center